OpenAI Acquires Orchestra Bio for Rosalind Life Sciences Model
Summary
OpenAI acquired Orchestra Bio, a four-year-old startup whose AI agents handle drug-discovery operations such as clinical trial scheduling and finances. Terms were not disclosed; Orchestra had raised about $20 million. OpenAI says it will fold the team and technology into Rosalind, its life sciences model, and Rosalind Workbench, which it says Moderna and Novo Nordisk use.
Key Points
- Orchestra Bio's investors include Andreessen Horowitz, Atria and 8VC, according to TechCrunch.
- OpenAI announced the acquisition on its website on Tuesday, October 20, 2026.
- OpenAI describes Rosalind Workbench as a harness for planning experiments and analyzing results.